GlassScriptPhysician profile
Sathvik Balaram
NPI 1942732151
$8,136.08
in general payments reported to CMS, 2019-2025
27 companies · $2,737 in 2025
The $2,737 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,176 · 2023: $2,021 · 2024: $2,202 · 2025: $2,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,909 · Education: $51.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,908.50 |
| Education | $51.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,557.58 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,528.80 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,058.49 | 2022-2025 | Dupixent |
| Genzyme Corporation | $924.59 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $449.37 | 2022-2025 | Cuvitru, Takhzyro |
| Biocryst US Sales Co., LLC | $373.15 | 2023-2025 | Orladeyo |
| Optinose US, INC. | $328.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $304.62 | 2023-2025 | |
| Amgen INC. | $297.11 | 2022-2025 | Tezspire |
| Kaleo, INC. | $210.57 | 2022-2024 | Auvi-Q |
| Grifols USA, LLC | $168.73 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $167.42 | 2023-2025 | Xolair |
| Pfizer INC. | $97.05 | 2023-2025 | |
| Csl Behring | $82.82 | 2025 | Andembry, Haegarda |
| Ionis Pharmaceuticals, INC. | $82.22 | 2025 | Dawnzera |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $79.59 | 2024-2025 | Taltz, Ebglyss |
| Teva Pharmaceuticals USA, INC. | $70.45 | 2022-2023 | Airduo Digihaler |
| Greer Laboratories, INC. | $60.31 | 2025 | Oralair |
| Paratek Pharmaceuticals, INC. | $55.29 | 2025 | Xhance |
| Aytu Biopharma, INC. | $45.40 | 2024-2025 | Karbinal |
| Ars Pharmaceuticals Operations, INC. | $42.58 | 2025 | Neffy |
| Organon LLC | $41.47 | 2025 | Vtama |
| Phadia US INC. | $26.90 | 2022 | |
| Galderma Laboratories, L.P. | $22.73 | 2025 | Nemluvio |
| Kedrion Biopharma, INC. | $20.84 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Incyte Corporation | $19.98 | 2024 | Opzelura |
| Blueprint Medicines Corporation | $19.45 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sathvik Balaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.